Oncolix, Inc. (ONCX) Starts Presentation at the 8th Annual LD Micro Invitational
Oncolix, Inc. (OTCQB: ONCX) became a public company in August 2017. The company is working on ProlantaTM, a novel drug that has a novel mechanism of action (autophagy). Prolanta has the potential to work in all gynecological cancers and breast cancer. The company is currently conducting a Phase 1 dose-escalation trial for the treatment of ovarian cancer. The company is seeking additional capital to expand the use of Prolanta in other cancers and to acquire new cancer assets. For more information, visit the company’s website at www.OncolixBio.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to…







